Next, we demonstrated that pharmacologic inhibition of STK17B translates into enhanced antitumor efficacy in combination with a checkpoint inhibitor in a highly immunogenic syngeneic tumor model (MCA205). This evidence concerns the gene STK17B and neoplasm.